{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:59:10Z","timestamp":1790384350924,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AbbVie GK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-01015-w","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:52:38Z","timestamp":1787723558000},"page":"2527-2549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Preferences Toward CGRP-Targeting Preventive Migraine Treatments in Japan: Discrete Choice Experiment"],"prefix":"10.1007","volume":"15","author":[{"given":"Hisaka","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-756X","authenticated-orcid":false,"given":"Toru","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Onomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15\u201322. https:\/\/doi.org\/10.1046\/j.1468-2982.1997.1701015.x.","journal-title":"Cephalalgia"},{"key":"1015_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37:1945\u201355. https:\/\/doi.org\/10.1080\/03007995.2021.1971179.","journal-title":"Curr Med Res Opin"},{"key":"1015_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2021","unstructured":"GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2021;23:344\u201381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3.","journal-title":"Lancet Neurol"},{"key":"1015_CR4","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1007\/s12325-022-02289-w","volume":"39","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, Ueda K, Komori M, et al. Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) study. Adv Ther. 2022;39:5176\u201390. https:\/\/doi.org\/10.1007\/s12325-022-02289-w.","journal-title":"Adv Ther"},{"key":"1015_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ncn3.70042","volume":"13","author":"N Araki","year":"2025","unstructured":"Araki N, Takeshima T, Igarashi H, et al. Clinical practice guideline for headache disorders 2021. Neurol Clin Neurosci. 2025;13:389\u2013407. https:\/\/doi.org\/10.1111\/ncn3.70042.","journal-title":"Neurol Clin Neurosci"},{"key":"1015_CR6","unstructured":"Optimal clinical use guidelines for galcanezumab (Emgality) in Japan. Tokyo: Ministry of Health, Labour and Welfare; 2021. https:\/\/www.mhlw.go.jp\/content\/12404000\/000768564.pdf. Accessed 6 Jan 2025"},{"key":"1015_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7.","journal-title":"Lancet"},{"key":"1015_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/head.14995","volume":"65","author":"S Kitamura","year":"2025","unstructured":"Kitamura S, Matsumori Y, Yamamoto T, et al. Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: a double-blind, randomized controlled trial. Headache. 2025;65:1403\u201312. https:\/\/doi.org\/10.1111\/head.14995.","journal-title":"Headache"},{"key":"1015_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695\u2013706. https:\/\/doi.org\/10.1056\/NEJMoa2035908.","journal-title":"N Engl J Med"},{"key":"1015_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:775\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(23)01049-8.","journal-title":"Lancet"},{"key":"1015_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251374569","volume":"45","author":"Y Matsumori","year":"2025","unstructured":"Matsumori Y, Yamada H, Nagaseki Y, et al. Atogepant for the preventive treatment of episodic migraine in Japanese participants: a phase 2\/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. 2025;45:3331024251374569. https:\/\/doi.org\/10.1177\/03331024251374569.","journal-title":"Cephalalgia"},{"key":"1015_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"key":"1015_CR13","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94:e1365\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","journal-title":"Neurology"},{"key":"1015_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43:3331024231159366. https:\/\/doi.org\/10.1177\/03331024231159366.","journal-title":"Cephalalgia"},{"key":"1015_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39:445\u201358. https:\/\/doi.org\/10.1177\/0333102418821662.","journal-title":"Cephalalgia"},{"key":"1015_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056247","volume":"8","author":"S Delestras","year":"2013","unstructured":"Delestras S, Roustit M, Bedouch P, et al. Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. PLoS ONE. 2013;8:e56247. https:\/\/doi.org\/10.1371\/journal.pone.0056247.","journal-title":"PLoS ONE"},{"key":"1015_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.amjsurg.2018.01.011","volume":"216","author":"TM Hughes","year":"2018","unstructured":"Hughes TM, Merath K, Chen Q, et al. Association of shared decision-making on patient-reported health outcomes and healthcare utilization. Am J Surg. 2018;216:7\u201312. https:\/\/doi.org\/10.1016\/j.amjsurg.2018.01.011.","journal-title":"Am J Surg"},{"key":"1015_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0272989X14551638","volume":"35","author":"LA Shay","year":"2015","unstructured":"Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making. 2015;35:114\u201331. https:\/\/doi.org\/10.1177\/0272989X14551638.","journal-title":"Med Decis Making"},{"key":"1015_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40120-023-00453-0","volume":"12","author":"J Seo","year":"2023","unstructured":"Seo J, Tervonen T, Ueda K, Zhang D, Danno D, Tockhorn-Heidenreich A. Discrete choice experiment to understand Japanese patients\u2019 and physicians\u2019 preferences for preventive treatments for migraine. Neurol Ther. 2023;12:651\u201368. https:\/\/doi.org\/10.1007\/s40120-023-00453-0.","journal-title":"Neurol Ther"},{"key":"1015_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40120-024-00663-0","volume":"13","author":"T Takeshima","year":"2024","unstructured":"Takeshima T, Yuasa A, Lloyd YM, et al. A discrete-choice experiment assessing the patient preferences and real-world experiences of patients with migraine in Japan. Neurol Ther. 2024;13:1661\u201383. https:\/\/doi.org\/10.1007\/s40120-024-00663-0.","journal-title":"Neurol Ther"},{"key":"1015_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value Health"},{"key":"1015_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19:300\u201315. https:\/\/doi.org\/10.1016\/j.jval.2016.04.004.","journal-title":"Value Health"},{"issue":"1","key":"1015_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health"},{"key":"1015_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","volume":"32","author":"MD Clark","year":"2014","unstructured":"Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32:883\u2013902. https:\/\/doi.org\/10.1007\/s40273-014-0170-x.","journal-title":"Pharmacoeconomics"},{"key":"1015_CR25","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212.","journal-title":"JAMA Neurol"},{"key":"1015_CR26","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442\u201354. https:\/\/doi.org\/10.1177\/0333102418779543.","journal-title":"Cephalalgia"},{"key":"1015_CR27","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211\u201321. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"key":"1015_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2515816320932573","volume":"3","author":"F Sakai","year":"2020","unstructured":"Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial. Cephalalgia Rep. 2020;3:1\u201310. https:\/\/doi.org\/10.1177\/2515816320932573.","journal-title":"Cephalalgia Rep"},{"key":"1015_CR29","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999\u20132008. https:\/\/doi.org\/10.1001\/jama.2018.4853.","journal-title":"JAMA"},{"key":"1015_CR30","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038.","journal-title":"N Engl J Med"},{"key":"1015_CR31","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1102\u201311. https:\/\/doi.org\/10.1111\/head.14178.","journal-title":"Headache"},{"key":"1015_CR32","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1092\u2013101. https:\/\/doi.org\/10.1111\/head.14169.","journal-title":"Headache"},{"key":"1015_CR33","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1705848.","journal-title":"N Engl J Med"},{"key":"1015_CR34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026\u201337. https:\/\/doi.org\/10.1177\/0333102418759786.","journal-title":"Cephalalgia"},{"key":"1015_CR35","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/head.13652","volume":"59","author":"F Sakai","year":"2019","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, et al. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache. 2019;59:1731\u201342. https:\/\/doi.org\/10.1111\/head.13652.","journal-title":"Headache"},{"key":"1015_CR36","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","volume":"61","author":"T Takeshima","year":"2021","unstructured":"Takeshima T, Sakai F, Hirata K, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache. 2021;61:927\u201335. https:\/\/doi.org\/10.1111\/head.14138.","journal-title":"Headache"},{"key":"1015_CR37","unstructured":"AbbVie Inc.  Highlights of prescribing information. QULIPTA (atogepant) full prescribing information. North Chicago: AbbVie Inc. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215206s004lbl.pdf. Accessed 6 Jan 2025"},{"key":"1015_CR38","unstructured":"AbbVie Deutschland GmbH & Co. KG. Annex I. Summary of product characteristics. AQUIPTA (atogepant) EPAR\u2014product information. 2023. Ludwigshafen: AbbVie Deutschland GmbH & Co. KG. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aquipta-epar-product-information_en.pdf. Accessed 6 Jan 2025"},{"key":"1015_CR39","unstructured":"Biohaven Pharmaceuticals. Highlights of prescribing information. NURTEC ODT (rimegepant) full prescribing information. 2022. New Haven: Biohaven Pharmaceuticals. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212728s009lbl.pdf. Accessed 6 Jan 2025"},{"key":"1015_CR40","unstructured":"Pfizer Europe MA EEIG. Annex I. Summary of product characteristics. VYDURA (rimegepant) EPAR\u2014product information. 2024Brussels: Pfizer Europe MA EEIG. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vydura-epar-product-information_en.pdf. Accessed 6 Jan 2025"},{"key":"1015_CR41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26:661\u201377. https:\/\/doi.org\/10.2165\/00019053-200826080-00004.","journal-title":"Pharmacoeconomics"},{"key":"1015_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219905","volume":"14","author":"M Trapero-Bertran","year":"2019","unstructured":"Trapero-Bertran M, Rodr\u00edguez-Mart\u00edn B, L\u00f3pez-Bastida J. What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review. PLoS ONE. 2019;14:e0219905. https:\/\/doi.org\/10.1371\/journal.pone.0219905.","journal-title":"PLoS ONE"},{"key":"1015_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jocm.2015.09.001","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Johnson FR, Kilambi V, Mohamed AF. Sample size and utility-difference precision in discrete-choice experiments: a meta-simulation approach. J Choice Model. 2015;16:50\u20137. https:\/\/doi.org\/10.1016\/j.jocm.2015.09.001.","journal-title":"J Choice Model"},{"key":"1015_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, Bridges JFP, Hauber B, et al. Conjoint analysis applications in health\u2014how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient. 2010;3:249\u201356. https:\/\/doi.org\/10.2165\/11539650-000000000-00000.","journal-title":"Patient"},{"key":"1015_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37:201\u201326. https:\/\/doi.org\/10.1007\/s40273-018-0734-2.","journal-title":"Pharmacoeconomics"},{"key":"1015_CR46","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/01441640902827623","volume":"29","author":"JM Rose","year":"2009","unstructured":"Rose JM, Bliemer MCJ. Constructing efficient stated choice experimental designs. Transp Rev. 2009;29:587\u2013617. https:\/\/doi.org\/10.1080\/01441640902827623.","journal-title":"Transp Rev"},{"key":"1015_CR47","unstructured":"Takeshima T, Sakai F, Suzuki N, et al. A simple migraine screening instrument: validation study in Japan. Japanese Journal of Headache. 2015;42:134\u201344. https:\/\/www.jhsnet.net\/gakkaishi\/gakkaishi_42-1.html"},{"key":"1015_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/head.14781","volume":"65","author":"JK Bougie","year":"2025","unstructured":"Bougie JK, Krupsky K, Beusterien K, Ladouceur MP, Mulvihill E. Patient preferences for preventive migraine treatments among Canadian adults: a discrete choice experiment. Headache. 2025;65:113\u201323. https:\/\/doi.org\/10.1111\/head.14781.","journal-title":"Headache"},{"key":"1015_CR49","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/head.14476","volume":"63","author":"TJ Schwedt","year":"2023","unstructured":"Schwedt TJ, Martin A, Kymes S, et al. Patient preferences for attributes of injected or infused preventive migraine medications: findings from a discrete choice experiment. Headache. 2023;63:484\u201393. https:\/\/doi.org\/10.1111\/head.14476.","journal-title":"Headache"},{"key":"1015_CR50","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/head.14386","volume":"62","author":"LT Hubig","year":"2022","unstructured":"Hubig LT, Smith T, Chua GN, et al. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache. 2022;62:1187\u201397. https:\/\/doi.org\/10.1111\/head.14386.","journal-title":"Headache"},{"key":"1015_CR51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/head.13498","volume":"59","author":"C Mansfield","year":"2019","unstructured":"Mansfield C, Gebben DJ, Sutphin J, et al. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 2019;59:715\u201326. https:\/\/doi.org\/10.1111\/head.13498.","journal-title":"Headache"},{"key":"1015_CR52","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/head.14739","volume":"64","author":"EG Martin","year":"2024","unstructured":"Martin EG, Kuziek J, Rasiah J, Orr SL. Evaluating patient and family preferences for acute and preventive pediatric headache treatment. Headache. 2024;64:950\u201366. https:\/\/doi.org\/10.1111\/head.14739.","journal-title":"Headache"},{"key":"1015_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/head.14430","volume":"63","author":"M Urtecho","year":"2023","unstructured":"Urtecho M, Wagner B, Wang Z, et al. A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes. Headache. 2023;63:185\u2013201. https:\/\/doi.org\/10.1111\/head.14430.","journal-title":"Headache"},{"key":"1015_CR54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/head.14255","volume":"62","author":"J Ailani","year":"2022","unstructured":"Ailani J, Winner P, Hartry A, et al. Patient preference for early onset of efficacy of preventive migraine treatments. Headache. 2022;62:374\u201382. https:\/\/doi.org\/10.1111\/head.14255.","journal-title":"Headache"},{"key":"1015_CR55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40271-021-00525-z","volume":"15","author":"J Seo","year":"2022","unstructured":"Seo J, Smith CA, Thomas C, et al. Patient perspectives and experiences of preventive treatments and self-injectable devices for migraine: a focus group study. Patient. 2022;15:93\u2013108. https:\/\/doi.org\/10.1007\/s40271-021-00525-z.","journal-title":"Patient"},{"key":"1015_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0998-8","volume":"20","author":"R Cowan","year":"2019","unstructured":"Cowan R, Cohen JM, Rosenman E, Iyer R. Physician and patient preferences for dosing options in migraine prevention. J Headache Pain. 2019;20:50. https:\/\/doi.org\/10.1186\/s10194-019-0998-8.","journal-title":"J Headache Pain"},{"key":"1015_CR57","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1526-4610.2007.00757.x","volume":"47","author":"MFP Peres","year":"2007","unstructured":"Peres MFP, Silberstein S, Moreira F, et al. Patients\u2019 preference for migraine preventive therapy. Headache. 2007;47:540\u20135. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00757.x.","journal-title":"Headache"},{"key":"1015_CR58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.242","volume":"20","author":"T Akaishi","year":"2019","unstructured":"Akaishi T, Takayama S, Ohsawa M, et al. Successful treatment of intractable menstrual migraine with the traditional herbal medicine tokishakuyakusan. J Gen Fam Med. 2019;20:118\u201321. https:\/\/doi.org\/10.1002\/jgf2.242.","journal-title":"J Gen Fam Med"},{"key":"1015_CR59","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40120-024-00690-x","volume":"14","author":"D Danno","year":"2025","unstructured":"Danno D, Suzuki S, Takizawa T, et al. The impact of migraine on the whole life course of patients: results from the OVERCOME (Japan) 2nd study. Neurol Ther. 2025;14:335\u201356. https:\/\/doi.org\/10.1007\/s40120-024-00690-x.","journal-title":"Neurol Ther"},{"key":"1015_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02046-8","volume":"26","author":"R Ishii","year":"2025","unstructured":"Ishii R, Takizawa T, Suzuki S, et al. Real-world use of over-the-counter medications by patients with migraine in Japan: results from the OVERCOME (Japan) 2nd study. J Headache Pain. 2025;26:107. https:\/\/doi.org\/10.1186\/s10194-025-02046-8.","journal-title":"J Headache Pain"},{"key":"1015_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315610","volume":"19","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Togo K, Igarashi A, Takeshima T. Clinical practice for migraine treatment and characteristics of medical facilities and physicians treating migraine: Insights from a retrospective cohort study using a Japanese claims database. PLoS ONE. 2024;19:e0315610. https:\/\/doi.org\/10.1371\/journal.pone.0315610.","journal-title":"PLoS ONE"},{"key":"1015_CR62","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/head.14721","volume":"64","author":"DC Buse","year":"2024","unstructured":"Buse DC, Sakai F, Matharu M, et al. Characterizing gaps in the preventive pharmacologic treatment of migraine: multi-country results from the CaMEO-I study. Headache. 2024;64:469\u201381. https:\/\/doi.org\/10.1111\/head.14721.","journal-title":"Headache"},{"key":"1015_CR63","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2147\/PPA.S496736","volume":"19","author":"C Whichello","year":"2025","unstructured":"Whichello C, Viktrup L, Varnado OJ, Quaife M, Trapali M, Tockhorn-Heidenreich A. patient preferences for episodic migraine medications: A discrete choice experiment of self-injectable versus oral treatments targeting calcitonin gene-related peptide pathway. Patient Prefer Adherence. 2025;19:839\u201353. https:\/\/doi.org\/10.2147\/PPA.S496736.","journal-title":"Patient Prefer Adherence"},{"key":"1015_CR64","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/head.14974","volume":"65","author":"RB Lipton","year":"2025","unstructured":"Lipton RB, Gandhi P, Myers K, Bussberg C, Stokes J, Nahas SJ. Patient preferences for the preventive treatment of episodic migraine in the United States: a discrete-choice experiment. Headache. 2025;65:1541\u201353. https:\/\/doi.org\/10.1111\/head.14974.","journal-title":"Headache"},{"key":"1015_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01737-y","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Ihara K, Watanabe N, et al. CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese Headache Society. J Headache Pain. 2024;25:39. https:\/\/doi.org\/10.1186\/s10194-024-01737-y.","journal-title":"J Headache Pain"},{"key":"1015_CR66","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/2168479015619202","volume":"50","author":"A Takayama","year":"2016","unstructured":"Takayama A, Narukawa M. Pharmaceutical pricing and reimbursement in Japan: for faster, more complete access to new drugs. Ther Innov Regul Sci. 2016;50:361\u20137. https:\/\/doi.org\/10.1177\/2168479015619202.","journal-title":"Ther Innov Regul Sci"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01015-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01015-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01015-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:02:41Z","timestamp":1790380961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01015-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01015-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hisaka Igarashi has received consulting fees from Sawai Pharmaceutical Co., Ltd., AbbVie GK, Pfizer Inc.; and lecture honoraria from Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K, Amgen K.K., Daiichi Sankyo Co., Ltd., and AbbVie GK. Toru Yamazaki, Hitomi Onomura and Hiroyuki Hozawa are employees of AbbVie GK and may hold AbbVie stocks\/stock options. Keigo Hanada and Tatsunori Murata are employees of CRECON Medical Assessment Inc., which received funding from AbbVie GK to conduct the study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects and the Declaration of Helsinki of 1964 and its later amendments. The study protocol was reviewed and approved by the Ethics Review Committee of Shiba Palace Clinic (Approval Number: 158252_rn-39651; Approval Date: February 27, 2025). Informed consent was obtained from all patients with migraine participating in the focus group interview, pilot survey, and main survey prior to the initiation of the investigation.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}